Investors might want to bet on Palisade Bio, Inc. (PALI), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates - ...

Carlsbad, CA, March 04, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage ...

Palisade Bio receives CAD$1.39 million in SR&ED credits for PALI-2108; Phase 1a/b UC study data expected mid-2025. The company is heavily dependent on the success of PALI-2108, which is still in ...

Carlsbad, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage ...

CARLSBAD - Palisade Bio, Inc. (NASDAQ: PALI), a clinical-stage biopharmaceutical company, has announced the receipt of 1.39 million Canadian dollars in Scientific Research and Experimental ...

Dr. Joerg Heyer, Head of Translational Science and Medicine of Palisade Bio highlights preclinical data for lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC ...

Carlsbad, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade”, "Palisade Bio”, or the "Company”), a clinical-stage biopharmaceutical company focused on developing and ...